- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03088930
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
January 19, 2022 updated by: University of Colorado, Denver
A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer
This study will evaluate the efficacy of crizotinib as induction therapy in participants with surgically resectable ALK rearrangement, ROS1 rearrangement, or MET exon 14 mutation positive NSCLC.
Study Overview
Detailed Description
Participants with stage IA-IIIA, surgically resectable lung adenocarcinoma with an activating alteration in ALK, ROS1 or MET will receive neoadjuvant treatment with crizotinib.
This neoadjuvant treatment will last 6 weeks and on the last day of dosing of crizotinib, participants will undergo surgical resection, followed by 5 years of follow-up via chart review.
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Denver
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Stage IA-IIIA NSCLC by 8th edition AJCC staging (that is deemed to be surgically resectable by a board certified thoracic surgeon.
- Staging by PET-CT scan and MRI brain showing no evidence of metastatic disease (mediastinoscopy is not required unless imaging is indeterminate and is then considered standard of care)
- Documented evidence of an ALK rearrangement (by FISH, IHC, or NGS), ROS1 rearrangement (by FISH or NGS), or MET oncogene as defined by MET exon 14 skipping (NGS), MET Y1003X mutation or MET gene fusion (NGS) in NSCLC tumor specimen by a CLIA-approved laboratory.
- Measurable disease defined by RECIST 1.1 criteria.
- Life expectancy of at least 24 months.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Age ≥ 18 years
- Have normal QT interval on ECG evaluation QT corrected Fridericia (QTcF) of ≤ 450 ms in males or ≤ 470 ms in females
Adequate organ function:
- Absolute neutrophil count (ANC) ≥1500/µL
- Platelets ≥75,000/µL
- Hemoglobin ≥ 10g/dL
- AST /ALT ≤ 2.5 x upper limit of normal (ULN)
- Total serum bilirubin ≤ 1.5 x ULN
- Serum creatinine ≤ 1.5 x UNL
- Serum amylase/lipase ≤ 1.5 x UNL
- Negative serum pregnancy test within 7 days of D1 of treatment in women of child bearing potential.
- If fertile, willing to use highly effective form of contraception (defined as a combination of at least two of the following methods: condom or other barrier methods, oral contraceptives, implantable contraceptives, intrauterine devices) during the dosing period and for at least 4 months after the dosing period.
- Ability to provide signed informed consent and willing and able to comply with all study requirements.
Exclusion Criteria:
- Stage IIIB or IV NSCLC.
- History or the presence of pulmonary interstitial disease, or drug-related pneumonitis.
- Malabsorption syndrome or other GI illness that could affect oral absorption of the study drug
- Inability to swallow oral medications
Have significant, uncontrolled or active cardiovascular disease, specifically including but restricted to:
- Myocardial infarction (MI) within 6 months of trial enrollment
- Unstable angina within 6 months of trial enrollment
- Congestive heart failure (CHF) with 6 months prior to trial enrollment
- Any history of ventricular arrhythmia
- Cerebrovascular accident or transient ischemic attack within 6 months of D1 of treatment
- Clinically significant atrial arrhythmia or severe baseline bradycardia defined as resting heart rate < 50 beat per minute
- Uncontrolled hypertension defined as baseline SBP> 160 and DBP > 100 on 3 separate clinic visits or past history of hypertensive urgency, emergency or encephalopathy
- Have active infection requiring antibiotics
- Pregnant or lactating female.
- Prior treatment with an ALK, ROS1 or MET inhibitor
- Any prior anticancer therapy for this diagnosis
- Any active cancer diagnosis (basal or squamous cell cancers allowed) within the last 5 years for which the patient is receiving active therapy or which is untreated. Any cancer diagnosis within the last 5 years that is considered "treated" and/ or on surveillance may be included in the trial.
- Have any condition or illness that, in the opinion of the investigator would compromise patient safety or interfere with evaluation of the study drug (including but not limited to HIV and HCV)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Neoadjuvant treatment with Crizotinib
Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib.
On the last day of dosing, patients will then undergo surgical resection.
5 years of follow-up will be done via chart review.
|
Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros).
Crizotinib will be given as a neoadjuvant therapy before surgical resection.
The recommended dose of crizotinib is 250mg orally.
Participants on this trial will receive this dose, unless dose modification is necessary.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Number of Participants With an Objective Tumor Response Rate
Time Frame: 6 weeks
|
Participants' tumor response to treatment will be compared from initial/pretreatment scan to 6 week scan using RECIST 1.1
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Number of Participants With Pathologic Response Rate
Time Frame: 37 months
|
Pathologic response rate is defined as < 50% of viable tumor present histologically in the resected tumor specimen.
|
37 months
|
Number of Participants With an Objective Response Rate
Time Frame: 6 weeks post treatment
|
Number of participants with response rate per RECIST 1.1
|
6 weeks post treatment
|
The Number of Participants With Disease-free Survival (DFS)
Time Frame: 37 months
|
DFS is defined as the time from treatment to the first of either disease recurrence or death from any cause.
|
37 months
|
Overall Survival (OS) Measured in Months
Time Frame: 37 months
|
OS is defined as the time from study enrollment to death from any cause.
|
37 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Tejas Patil, MD, PhD, University of Colorado, Denver
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 13, 2017
Primary Completion (ACTUAL)
January 13, 2021
Study Completion (ACTUAL)
January 13, 2021
Study Registration Dates
First Submitted
March 17, 2017
First Submitted That Met QC Criteria
March 17, 2017
First Posted (ACTUAL)
March 23, 2017
Study Record Updates
Last Update Posted (ACTUAL)
February 11, 2022
Last Update Submitted That Met QC Criteria
January 19, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Crizotinib
Other Study ID Numbers
- 16-2025.cc
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer, Nonsmall Cell
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedNonsmall Cell Lung Cancer Stage III | Nonsmall Cell Lung Cancer, Stage IIUnited States
-
Medical University of South CarolinaTerminatedNonsquamous Nonsmall Cell Neoplasm of Lung | Nonsmall Cell Lung Cancer Stage IIIUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteRecruitingNonsmall Cell Lung Cancer | Nonsmall Cell Lung Cancer Stage III | Unresectable Non-Small Cell Lung Carcinoma | Nonsmall Cell Lung Cancer, Stage IIUnited States
-
BeiGeneActive, not recruitingNonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)United States, China, Korea, Republic of, France, Spain, Australia, Austria
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingNonsmall-cell Lung CancerChina
-
MIPO ClinicCompletedNonsmall-cell Lung CancerKazakhstan
-
Zealand University HospitalCompletedMetastatic Nonsmall Cell Lung CancerDenmark
-
Chang Gung Memorial HospitalCompletedAdvanced Nonsmall Cell Lung CancerTaiwan
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedNonsmall Cell Lung Cancer | Nonsmall Cell Lung Cancer StageUnited States
-
Northwestern UniversityCompletedAdvanced Nonsmall Cell Lung CancerUnited States
Clinical Trials on Crizotinib
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...Not yet recruitingNon-Small Cell Lung CancerUnited States
-
PfizerWithdrawnCarcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
-
Samsung Medical CenterCompletedc-MET Positive Gastric CancerKorea, Republic of
-
PfizerCompletedRenal ImpairmentUnited States
-
PfizerCompleted
-
European Organisation for Research and Treatment...PfizerCompletedLocally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 | Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma | Locally Advanced... and other conditionsFrance, Belgium, Netherlands, Germany, United Kingdom, Italy, Norway, Poland, Slovakia, Slovenia
-
PfizerCompleted
-
PfizerCompletedHealthy VolunteerUnited States